Literature DB >> 18684977

CD28 costimulation is essential for human T regulatory expansion and function.

Tatiana N Golovina1, Tatiana Mikheeva, Megan M Suhoski, Nicole A Aqui, Victoria C Tai, Xiaochuan Shan, Ronghua Liu, R Robert Balcarcel, Nancy Fisher, Bruce L Levine, Richard G Carroll, Noel Warner, Bruce R Blazar, Carl H June, James L Riley.   

Abstract

The costimulatory requirements required for peripheral blood T regulatory cells (Tregs) are unclear. Using cell-based artificial APCs we found that CD28 but not ICOS, OX40, 4-1BB, CD27, or CD40 ligand costimulation maintained high levels of Foxp3 expression and in vitro suppressive function. Only CD28 costimulation in the presence of rapamycin consistently generated Tregs that consistently suppressed xenogeneic graft-vs-host disease in immunodeficient mice. Restimulation of Tregs after 8-12 days of culture with CD28 costimulation in the presence of rapamycin resulted in >1000-fold expansion of Tregs in <3 wk. Next, we determined whether other costimulatory pathways could augment the replicative potential of CD28-costimulated Tregs. We observed that while OX40 costimulation augmented the proliferative capacity of CD28-costimulated Tregs, Foxp3 expression and suppressive function were diminished. These studies indicate that the costimulatory requirements for expanding Tregs differ from those for T effector cells and, furthermore, they extend findings from mouse Tregs to demonstrate that human postthymic Tregs require CD28 costimulation to expand and maintain potent suppressive function in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18684977      PMCID: PMC2556987          DOI: 10.4049/jimmunol.181.4.2855

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  77 in total

1.  FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression.

Authors:  Bin Li; Arabinda Samanta; Xiaomin Song; Kathryn T Iacono; Kathryn Bembas; Ran Tao; Samik Basu; James L Riley; Wayne W Hancock; Yuan Shen; Sandra J Saouaf; Mark I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-07       Impact factor: 11.205

2.  Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy.

Authors:  Beom K Choi; Young H Kim; Woo J Kang; Sun K Lee; Kwang H Kim; Su M Shin; Wayne M Yokoyama; Tae Y Kim; Byoung S Kwon
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

Review 3.  What does the future hold for cell-based tolerogenic therapy?

Authors:  Jeffrey A Bluestone; Angus W Thomson; Ethan M Shevach; Howard L Weiner
Journal:  Nat Rev Immunol       Date:  2007-08       Impact factor: 53.106

4.  Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.

Authors:  Megan M Suhoski; Tatiana N Golovina; Nicole A Aqui; Victoria C Tai; Angel Varela-Rohena; Michael C Milone; Richard G Carroll; James L Riley; Carl H June
Journal:  Mol Ther       Date:  2007-03-20       Impact factor: 11.454

5.  OX40 costimulation turns off Foxp3+ Tregs.

Authors:  Minh Diem Vu; Xiang Xiao; Wenda Gao; Nicolas Degauque; Ming Chen; Alexander Kroemer; Nigel Killeen; Naoto Ishii; Xian Chang Li
Journal:  Blood       Date:  2007-06-15       Impact factor: 22.113

6.  Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells.

Authors:  Takanori So; Michael Croft
Journal:  J Immunol       Date:  2007-08-01       Impact factor: 5.422

7.  DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells.

Authors:  Udo Baron; Stefan Floess; Georg Wieczorek; Katrin Baumann; Andreas Grützkau; Jun Dong; Andreas Thiel; Tina J Boeld; Petra Hoffmann; Matthias Edinger; Ivana Türbachova; Alf Hamann; Sven Olek; Jochen Huehn
Journal:  Eur J Immunol       Date:  2007-09       Impact factor: 5.532

8.  CD27 expression discriminates between regulatory and non-regulatory cells after expansion of human peripheral blood CD4+ CD25+ cells.

Authors:  Richard C Duggleby; Tovah N F Shaw; Lorna B Jarvis; Gurman Kaur; J S Hill Gaston
Journal:  Immunology       Date:  2007-05       Impact factor: 7.397

9.  Differential CD28 and inducible costimulatory molecule signaling requirements for protective CD4+ T-cell-mediated immunity against genital tract Chlamydia trachomatis infection.

Authors:  Ellen Marks; Martina Verolin; Anneli Stensson; Nils Lycke
Journal:  Infect Immun       Date:  2007-07-16       Impact factor: 3.441

10.  Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.

Authors:  Sarah E Allan; Sarah Q Crome; Natasha K Crellin; Laura Passerini; Theodore S Steiner; Rosa Bacchetta; Maria G Roncarolo; Megan K Levings
Journal:  Int Immunol       Date:  2007-02-27       Impact factor: 4.823

View more
  74 in total

1.  New insights on OX40 in the control of T cell immunity and immune tolerance in vivo.

Authors:  Xiang Xiao; Weihua Gong; Gulcin Demirci; Wentao Liu; Silvia Spoerl; Xiufeng Chu; D Keith Bishop; Laurence A Turka; Xian C Li
Journal:  J Immunol       Date:  2011-12-05       Impact factor: 5.422

2.  TCR affinity and specificity requirements for human regulatory T-cell function.

Authors:  Gabriela Plesa; Lingjie Zheng; Andrew Medvec; Caleph B Wilson; Camila Robles-Oteiza; Nathaniel Liddy; Alan D Bennett; Jessie Gavarret; Annelise Vuidepot; Yangbing Zhao; Bruce R Blazar; Bent K Jakobsen; James L Riley
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

3.  Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly.

Authors:  Anandharaman Veerapathran; Joseph Pidala; Francisca Beato; Xue-Zhong Yu; Claudio Anasetti
Journal:  Blood       Date:  2011-09-23       Impact factor: 22.113

4.  Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus.

Authors:  K Singh; N Kozyr; L Stempora; A D Kirk; C P Larsen; B R Blazar; L S Kean
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

Review 5.  Strategies for combining immunotherapy with radiation for anticancer therapy.

Authors:  Steven N Seyedin; Jonathan E Schoenhals; Dean A Lee; Maria A Cortez; Xiaohong Wang; Sharareh Niknam; Chad Tang; David S Hong; Aung Naing; Padmanee Sharma; James P Allison; Joe Y Chang; Daniel R Gomez; John V Heymach; Ritsuko U Komaki; Laurence J Cooper; James W Welsh
Journal:  Immunotherapy       Date:  2015-08-27       Impact factor: 4.196

6.  Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation.

Authors:  Taylor H Schreiber; Dietlinde Wolf; Matthew S Tsai; Jackie Chirinos; Vadim V Deyev; Louis Gonzalez; Thomas R Malek; Robert B Levy; Eckhard R Podack
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

7.  CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients.

Authors:  Andrew J Rech; Rosemarie Mick; Sunil Martin; Adri Recio; Nicole A Aqui; Daniel J Powell; Theresa A Colligon; Jennifer A Trosko; Leah I Leinbach; Charles H Pletcher; Carol K Tweed; Angela DeMichele; Kevin R Fox; Susan M Domchek; James L Riley; Robert H Vonderheide
Journal:  Sci Transl Med       Date:  2012-05-16       Impact factor: 17.956

Review 8.  Systems biology of lupus: mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment.

Authors:  Andras Perl
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

9.  Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease.

Authors:  Steve Pino; Michael A Brehm; Laurence Covassin-Barberis; Marie King; Bruce Gott; Thomas H Chase; Jennifer Wagner; Lisa Burzenski; Oded Foreman; Dale L Greiner; Leonard D Shultz
Journal:  Methods Mol Biol       Date:  2010

Review 10.  Next-generation regulatory T cell therapy.

Authors:  Leonardo M R Ferreira; Yannick D Muller; Jeffrey A Bluestone; Qizhi Tang
Journal:  Nat Rev Drug Discov       Date:  2019-09-20       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.